News | April 07, 2014

New Prostate Cancer Treatment Uses MRI to Guide Ultrasound Ablation

New method could provide an alternative to "watch and wait" or surgery

April 7, 2014 — A new multicenter clinical trial seeks to offer men another option for treating prostate cancer, one that physicians hope will treat cancers with fewer side effects.

As part of that trial, City of Hope in Duarte, Calif., has become the first center in the nation to perform a new procedure using a focused beam of ultrasound energy to “ablate” the prostate cancer. Traditional treatment approaches, such as surgery and radiation, are potentially very effective in treating prostate cancer, but some men are left facing incontinence or impotence. Men with very slow-growing cancers may choose a “watch and wait” approach, monitoring the cancer and determining appropriate interventions if they become necessary.

In this ultrasound ablation technique, the ultrasound is guided by MRI (magnetic resonance imaging) technology, allowing the ultrasound to be delivered very precisely to the site of the cancer. The imaging provides real-time thermal feedback, which helps physicians determine at the time of the procedure if enough ultrasound was delivered to the targeted area.

“The potential is that if we could provide a focal therapy that has a much lower risk profile compared to standard therapies, this may potentially be an option for men who choose not to ‘watch and wait,’” said Jeffrey Wong, M.D., chair of radiation oncology at City of Hope and a primary investigator on the trial. “At this time, the treatment is under trial and still being evaluated.”

The technology is approved by the U.S. Food and Drug Administration (FDA) to treat painful bone metastases, and has been used in other countries to treat prostate cancer.

Jaime Negrette, who lives in Long Beach, was diagnosed with prostate cancer by a PSA (prostate-specific antigen) test and sought out an alternative treatment to surgery or radiation. He was treated in mid-November 2013. About six months after treatment, Negrette will know more definitively if the treatment was a success, but so far, he has had no side effects and is doing well.

“I’ve had friends who have been treated for prostate cancer,” he said. “Some men have issues that last long after their prostate was removed, so I was very happy to have another choice.”

The trial includes men with low-risk prostate cancer, with no more than two areas in the prostate gland involved with cancer. The multicenter feasibility trial is ongoing.

For more information: www.cityofhope.org

Related Content

MRI Metal Artifact Reduction Poses Minimal Thermal Risk to Hip Arthroplasty Implants
News | Magnetic Resonance Imaging (MRI) | May 23, 2019
Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
360 Photos | Magnetic Resonance Imaging (MRI) | May 17, 2019
This is a dedicated cardiac Siemens 1.5T MRI system installed at the Baylor Scott White Heart Hospital in Dallas.
Miami Cardiac and Vascular Institute Implements Philips Ingenia Ambition X 1.5T MRI
News | Magnetic Resonance Imaging (MRI) | May 17, 2019
Miami Cardiac & Vascular Institute announced the implementation of Philips’ Ingenia Ambition X 1.5T MR, the world’s...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Magnetic Resonance Imaging (MRI) | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...